open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:
Get Citation

55. How often should we obtain complete blood counts (CBC's) from patients receiving radical radiation therapy?

R. Dziadziuszko, K. Sosińska-Mielcarek, E. Szutowicz-Zielinska, J. Jassem
DOI: 10.1016/S1507-1367(01)70425-7
·
Rep Pract Oncol Radiother 2001;6(1):52.

open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:

Abstract

Data on factors influencing decline in peripheral blood counts during radiation treatment are sparse and no guidelines exist on the appropriate frequency of obtaining CBC's from the patients.

Patients and methods

A series of charts from 460 consecutive patients receiving radiotherapy in 1995 and 1996 was reviewed. In the final database, the data from patients receiving definitive radiotherapy with information on baseline CBC's and at least two results during treatment were included (183 patients, 810 results). Critical nadir values of haemoglobin (HGB), white blood cells (WBC) and platelets (PLT) requiring further tests and interventions were defined as follows: HGB<9.0 g/dL, WBC<2.000/mm3, PLT<100/mm3. For statistical analysis, logistic regression was used separately for each parameter and then the prognostic model of obtaining at least one nadir value in all tests performed in one patient was developed.

Results

Of 183 patients, at least one nadir value was observed in 17 patients (9%). Pre-treatment CBC was very strong and the only predictor of nadirs – the other variables were not significant in the final model. The probability of at least one nadir during treatment was 35% if one of the following pre-treatment CBC values was noted: HGB<11.0 g/dL, WBC<5.000/mm3 or PLT<150/mm3. A very low nadir probability of 1.6% was observed in the remaining group of patients.

Conclusion

Outside clinical trials, monitoring of CBC's in patients receiving radical radiation treatment should be performed if baseline values are below the proposed limits or other cytotoxic therapy is given.

Abstract

Data on factors influencing decline in peripheral blood counts during radiation treatment are sparse and no guidelines exist on the appropriate frequency of obtaining CBC's from the patients.

Patients and methods

A series of charts from 460 consecutive patients receiving radiotherapy in 1995 and 1996 was reviewed. In the final database, the data from patients receiving definitive radiotherapy with information on baseline CBC's and at least two results during treatment were included (183 patients, 810 results). Critical nadir values of haemoglobin (HGB), white blood cells (WBC) and platelets (PLT) requiring further tests and interventions were defined as follows: HGB<9.0 g/dL, WBC<2.000/mm3, PLT<100/mm3. For statistical analysis, logistic regression was used separately for each parameter and then the prognostic model of obtaining at least one nadir value in all tests performed in one patient was developed.

Results

Of 183 patients, at least one nadir value was observed in 17 patients (9%). Pre-treatment CBC was very strong and the only predictor of nadirs – the other variables were not significant in the final model. The probability of at least one nadir during treatment was 35% if one of the following pre-treatment CBC values was noted: HGB<11.0 g/dL, WBC<5.000/mm3 or PLT<150/mm3. A very low nadir probability of 1.6% was observed in the remaining group of patients.

Conclusion

Outside clinical trials, monitoring of CBC's in patients receiving radical radiation treatment should be performed if baseline values are below the proposed limits or other cytotoxic therapy is given.

Get Citation
About this article
Title

55. How often should we obtain complete blood counts (CBC's) from patients receiving radical radiation therapy?

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 6, No 1 (2001)

Pages

52

Published online

2001-01-01

DOI

10.1016/S1507-1367(01)70425-7

Bibliographic record

Rep Pract Oncol Radiother 2001;6(1):52.

Authors

R. Dziadziuszko
K. Sosińska-Mielcarek
E. Szutowicz-Zielinska
J. Jassem

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl